GBRADEN%MITVMC.BITNET@oac.ucla.edu (Glen Braden) (08/13/90)
Hello again,
Recently I asked this list about compound-q. I want to thank those
who responded. My friend was very happy to receive the telephone numbers
that were supplied by this list. He is still unsure of his decision to
start treatment with compound-q. He had recently stop AZT, because of
enormous amount of weight he was losing. Someone had recommended that
he check into treatment with PEPTIDE-T, so he asked me to submit a request
for information on this list about PEPTIDE-T.
Thank you in advance... GlenGBRADEN%MITVMC.BITNET@oac.ucla.edu (Glen Braden) (08/15/90)
the following from a friend via private EMAIL. I am forwarding it to the
list to benefit anyone else who is interest in PEPTIDE-T.
Glen Braden
=======================================================================
From AIDS: Facts without Fiction.
A new AIDS-therapy test is being conducted in Sweden. Physicians of the
Karolinska Institute in Stockholm want to treat 18 AIDS patients with a new
medication called Peptide T. European and American scientists repeat the basic
experiments on which the test was built: - the Swedish claim that Peptid T can
prevent the infection of white blood cells with HIV.
Pepiide T is a chain of 8 amino acides, 5 of which carry names that start
with the letter T - hence the name. The same order of amino acids occurs in
the viral protein gp120, which is in the viral envelope and is involved in the
attachment of the virus to the T4 lymphocyte.
Candance Pert and her colleagues at the National Institute of Health in
Bethesda first reported on Peptide T in 1986. These researchers claim that
peptide T is able to block the T4 lymphocyte receptor, which attaches HIV to
the cell. If this were the case, it would indeed inhibit the infection of the
cell with HIV. This finding might be helpful in the development of a vaccine
against AIDS. On the other hand, Peptide T or other related substances could
prevent the spread of the virus in already infected patients.
In itself, Peptide T is not toxic, yet it may influence the immune system.
The University of Ca, Los Angeles, held a conference on Peptide T in April
1987. All particiipants invormed Candace Pert that they were not able to
repeat the experiments on the T4 receptor block via Peptide T. Even Professor
Wigzell, Professor of Immunology at the Karolinska Institute in Stockholm,
could not confirm the results. According to Wigzell, Peptide T cannot
influence the attachment to the envelope protein gp120 or the viral
replication in vitro, in the laboratory.
The experiments with Peptide T at the Karolinska Institute do not seem to
be too promising because the experimental basis for the clinical trials is
lacking. Many scientists would not consider clinical tests with patients
because of this. It shows how desperate the situation is in the search for an
efficent treatment of AIDS that some scientists are prepared to carry out
clinical trials which rest on no adequate experimental basis.
Other treatments mentioned were Avarol ad Avaron. Ddeoxycytidin and
Ampligen, Foscarnet, Ribavirin, Contracan, Suramin, AL 721... some success
on this one, but research is limited... Padma 28, Autovaccines(not much
hope here they say), New Vaccines(not much hope here either), Anti
Ideotype Research, Irradiated HIV as basis of a vaccine against AIDS.
There was also talk about "VILA" being a "trigger", but this is brand
new. With out "VILA", AIDS might not start, but they sort of don't know
what "VILA" is, simply that it seems to "be there". Why? They are looking
into it.
=======================================================================